Komori
ReproCELL (4978) · RiskWorsened

Risk of Future Tax Burden from Tax Loss Carryforwards

First written in FY2017. 4 of 8 entries say "Worsened", first in FY2020. Latest entry: FY2026.

8entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017 – FY2018WorsenedFY2020 – FY2023MitigatedFY2024 – FY20252017: 120172018: 120182019: 020192020: 120202021: 120212022: 020222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
Increase in corporate tax burden due to the disallowance and reversal of tax loss carryforwardsA theme 125 companies write about · 125 as a headwind · 0 as a tailwind

ReproCELL moved to the "Worse" side of this theme in 2020, 4 years before the typical company in this theme (2024).

The whole theme swung hardest in 2026: 28 of 56 companies on the "Worse" side.

31 other companies' latest entry also says "Worsened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 125 companies compared. The sentences above are computed from all 125.
Full recordFilings, disclosures and news, newest first
  1. FY2026WorsenedAnnual report

    「Tax loss carryforwards: ¥1,808.872 million」

    Tax loss carryforwards increased from ¥1,588.399 million in the previous fiscal year to ¥1,808.872 million, numerically increasing the risk of an impact on future taxable income, corporate tax expense and other items.
  2. FY2025MitigatedAnnual report

    「Tax loss carryforwards (Note): ¥1,588.399 million」

    Tax loss carryforwards decreased from ¥1,634.314 million in the previous fiscal year to ¥1,588.399 million. The risk of an impact on future taxable income, corporate tax expense and other items remains, but the balance has narrowed numerically.
  3. FY2024MitigatedAnnual report

    「Tax loss carryforwards: ¥1,634.314 million」

    Tax loss carryforwards decreased from ¥1,736.886 million in the previous fiscal year to ¥1,634.314 million. The risk of an impact on future taxable income, corporate tax expense and other items remains, but the balance has narrowed numerically.
  4. FY2023WorsenedAnnual report

    「Tax loss carryforwards: ¥1,736.886 million」

    Tax loss carryforwards increased from ¥1,651.800 million in the previous consolidated fiscal year to ¥1,736.886 million. The risk of an impact on future taxable income, corporate tax expense, profit and cash flow has increased numerically.
  5. FY2021WorsenedAnnual report

    「Tax loss carryforwards: ¥1,475.976 million」

    Tax loss carryforwards increased from ¥1,243.859 million in the previous fiscal year to ¥1,475.976 million, numerically increasing the risk of an impact on future taxable income, corporate tax expense and other items.
  6. FY2020WorsenedAnnual report

    「Tax loss carryforwards: ¥1,243.859 million」

    The amount of tax loss carryforwards increased from ¥1,025.034 million in the previous fiscal year to ¥1,243.859 million. The Company continues to disclose the risk of an impact on future taxable income, corporate tax expense and other items.
  7. FY2018RestatedAnnual report

    「The Company currently has tax loss carryforwards.」

    The Company reiterated the risk that tax loss carryforwards may affect future taxable income, corporate tax expense, profit and cash flow.
  8. FY2017First statedAnnual report

    「The Company currently has tax loss carryforwards. If, as a result of progress under its business plan and improved business performance, the Company becomes unable to deduct the tax loss carryforwards from taxable income, corporate tax, inhabitant tax and enterprise tax based on the normal tax rates will be recorded. This may affect net income or net loss attributable to owners of the parent and cash flow.」

    The Company disclosed the existence of tax loss carryforwards and their potential impact on future tax expense, profit and cash flow if the deductions become unavailable.
Moved together

"Impairment Risk for Goodwill and Intangible Assets at Overseas Subsidiaries" moved the same way as this thread, in the same document, in 5 of its 8 moves.

543322★123456
  1. ★This thread
  2. 1Impairment Risk for Goodwill and Intangible Assets at Overseas Subsidiaries5×
  3. 2Persistent losses as upfront investment and R&D expenses precede revenue generation4×
  4. 3Risk of delayed elimination of accumulated deficits3×
  5. 4Fiscal year ending March 2023: net sales of ¥3,565 million and ordinary profit of ¥491 million3×
  6. 5Raising Funds for Cell Therapy Product Development and Clinical Trials through the 12th Series of Stock Acquisition Rights2×
  7. 6Exclusive development and marketing of Stemchymal® in Japan2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Future Tax Burden from Tax Loss Carryforwards | ReproCELL Incorporated (4978) | Komori